ArticleAdvances in therapy2026
Real-World Characteristics, Treatment Patterns, and Clinical Outcomes of Patients Initiated on Macitentan/Tadalafil Single-Tablet Combination Therapy in the United States.
Article in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPulmonary arterial hypertension (PAH) is life-threatening and often complicated by comorbidities. Although endothelin receptor antagonist (ERA) plus phosphodiesterase 5 inhibitor (PDE5i) dual therapy is guideline recommended, real-world treatment varies. Macitentan/tadalafil fixed-dose combination (M/T FDC) is a once-daily single-tablet dual therapy approved in March 2024. This study characterized patient characteristics, treatment patterns, and exploratory outcomes.
methodsIn this retrospective chart review, 50 US healthcare providers reviewed patient charts during structured interviews. Patients were categorized as ERA/PDE5i/soluble guanylate cyclase (sGC)-naïve, escalated from monotherapy, or switched from ERA plus PDE5i/sGC combination therapy. Outcomes included baseline characteristics, treatment patterns, reasons for M/T FDC initiation, 6-min walk distance (6MWD), brain natriuretic peptide (BNP), and PAH-related hospitalizations.
resultsProviders reviewed 144 charts; 83.3% of patients had at least one comorbidity. Overall, 51.4% switched from dual therapy, 28.5% escalated from monotherapy, and 20.1% were ERA/PDE5i/sGC-naïve. Naïve patients frequently had connective tissue disease-associated or drug- and toxin-induced PAH. Reduced pill burden was the leading reason for initiation. Among patients without concomitant prostacyclin or activin signaling inhibitor initiation or escalation and with paired baseline and follow-up data, mean favorable numerical changes were observed: 6MWD increased by 51.0 m (355.2-406.2; n = 36), BNP decreased by 167.8 pg/mL (357.0-189.2; n = 29), and PAH-related hospitalizations decreased from 0.18 to 0.05 events per patient (n = 65) over approximately 3 months.
conclusionM/T FDC is being adopted across diverse US PAH populations, including patients with comorbidities, most commonly to reduce pill burden and simplify treatment administration. Exploratory descriptive analyses showed favorable numerical changes in selected clinical parameters among patients with available paired data. However, because the study was retrospective, non-comparative, and not powered for hypothesis testing, these findings should be interpreted as hypothesis-generating. These results provide early insights into use of M/T FDC use and identify areas for future longitudinal and comparative research.
Indexed as
Identifiers
42848186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.